<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646100</url>
  </required_header>
  <id_info>
    <org_study_id>TACE1</org_study_id>
    <nct_id>NCT00646100</nct_id>
  </id_info>
  <brief_title>Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis</brief_title>
  <acronym>TACEHCC</acronym>
  <official_title>Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcatheter arterial chemoembolization (TACE) had been proved to improve the survivals for
      middle stage hepatocellular carcinoma (HCC), but for advanced stage HCC its' efficacy had not
      been proved. The investigators hypothesize that TACE also improve the survivals for advanced
      stage HCC. Thus, the investigators carried out this prospective control study to find out if
      the survivals for patients after TACE better than only best support or not.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival rates</measure>
    <time_frame>6, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>6, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>best support care</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transcatheter arterial chemoembolization</intervention_name>
    <description>chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.</description>
    <arm_group_label>TACE</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European
             Association for the Study of the Liver (EASL)

          -  Tumor size &gt;7 cm with a portal vein invasion, and the tumor was considered to be
             unresectable

          -  No previous HCC directed treatment

          -  Eastern Co-operative Group performance status 0-1

          -  Liver function: Child's A

        Exclusion Criteria:

          -  Avascular tumor

          -  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or
             hepatic encephalopathy

          -  underlying serve cardiac or renal diseases

          -  Known or suspected allergy to the investigational agent or any agent given in
             association with this trial

          -  Diffuse-type HCC

          -  For patients with main portal vein occlusion, no adequate collateral circulation
             around the occluded portal vein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jinqing li, MD</last_name>
    <role>Study Director</role>
    <affiliation>cancer canter sun yat-set university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Canter Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36.</citation>
    <PMID>16250051</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>March 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>transcatheter arterial chemoembolization</keyword>
  <keyword>prospective control study</keyword>
  <keyword>best support care</keyword>
  <keyword>survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

